Piper Sandler Cuts Perspective Therapeutics (NYSEAMERICAN:CATX) Price Target to $14.00

Perspective Therapeutics (NYSEAMERICAN:CATX) had its price objective trimmed by Piper Sandler from $16.00 to $14.00 in a report released on Tuesday,Benzinga reports. The firm currently has an overweight rating on the stock.

CATX has been the topic of a number of other reports. Wedbush restated an “outperform” rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a research note on Tuesday, May 5th. BTIG Research reiterated a “buy” rating on shares of Perspective Therapeutics in a research note on Friday, July 24th. Eight research analysts have rated the stock with a Buy rating, According to MarketBeat, Perspective Therapeutics presently has an average rating of “Buy” and an average price target of $12.38.

Perspective Therapeutics Price Performance

NYSEAMERICAN:CATX opened at $3.10 on Tuesday. The business has a fifty day simple moving average of $3.08 and a two-hundred day simple moving average of $3.94. Perspective Therapeutics has a 1 year low of $1.96 and a 1 year high of $6.16.

Perspective Therapeutics (NYSEAMERICAN:CATX) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.03. The firm had revenue of $0.08 million for the quarter, compared to analysts’ expectations of $0.09 million. Perspective Therapeutics had a negative return on equity of 44.22% and a negative net margin of 28,467.97%. On average, equities analysts predict that Perspective Therapeutics will post -1.07 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. AXQ Capital LP lifted its stake in Perspective Therapeutics by 24.2% in the 4th quarter. AXQ Capital LP now owns 12,749 shares of the company’s stock worth $35,000 after purchasing an additional 2,481 shares in the last quarter. Deutsche Bank AG increased its stake in Perspective Therapeutics by 6.1% in the 4th quarter. Deutsche Bank AG now owns 54,245 shares of the company’s stock worth $149,000 after acquiring an additional 3,119 shares during the last quarter. Vontobel Holding Ltd. increased its stake in Perspective Therapeutics by 25.0% in the 4th quarter. Vontobel Holding Ltd. now owns 25,000 shares of the company’s stock worth $69,000 after acquiring an additional 5,000 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in shares of Perspective Therapeutics by 184.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock valued at $29,000 after acquiring an additional 5,475 shares in the last quarter. Finally, Wealth Effects LLC boosted its position in shares of Perspective Therapeutics by 32.0% during the 1st quarter. Wealth Effects LLC now owns 33,000 shares of the company’s stock valued at $138,000 after acquiring an additional 8,000 shares during the last quarter. Hedge funds and other institutional investors own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.